Skip to content

Study · Animal study (in vivo) · rat · 1998

3 results

Melanocortin mediated inhibition of feeding behavior in rats.

Murphy B, Nunes CN, Ronan JJ, Harper CM, Beall MJ, Hanaway M, Fairhurst AM, Van der Ploeg LH, MacIntyre DE, Mellin TN

Neuropeptides1 Dec 1998Cited by 87 (Europe PMC)

PMID9920446 (opens in a new tab)DOI10.1016/s0143-4179(98)90077-4 (opens in a new tab)PepBankPUB-09920446
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII given into the third ventricle inhibited food intake in a dose-dependent way.

    In plain wordsIn rats, MTII given into the brain lowered food intake, more so at higher doses.

    Peptide
    Melanotan II
    Outcome
    DecreaseSpontaneous nocturnal food intake after MTII
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular (third ventricle)As given in this study (rat).

    Source sentences

    Summary
    Dose-dependent inhibition or stimulation of food intake was observed with MTII or SHU9119, respectively.
    1 context sentence
    Summary · context
    To evaluate the involvement of melanocortins in spontaneous nocturnal feeding, the synthetic melanocortin receptor agonist, MTII and the antagonist, SHU9119 were administered ICV (third ventricle) alone and in combination.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, MTII dose-dependently inhibited food intake induced by NPY, and the highest dose abolished the NPY feeding response.

    In plain wordsIn rats, MTII reduced the extra eating caused by NPY, and the top dose blocked it fully.

    Peptide
    Melanotan II
    Outcome
    DecreaseNPY-induced food intake after MTII
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    MTII inhibited food intake induced by 5.0 microg hNPY in a dose dependent manner with the highest dose tested abolishing the NPY feeding response.
    1 context sentence
    Summary · context
    To evaluate the involvement of melanocortins in spontaneous nocturnal feeding, the synthetic melanocortin receptor agonist, MTII and the antagonist, SHU9119 were administered ICV (third ventricle) alone and in combination.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 03AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome

    In rats, co-injection of equal concentrations of MTII and the antagonist SHU9119 gave food intake indistinguishable from controls.

    In plain wordsIn rats, giving MTII together with a blocker gave food intake like controls.

    Peptide
    Melanotan II
    Outcome
    No significant changeFood intake after MTII plus SHU9119 co-injection
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Co-injections containing equal concentrations of MTII and SHU9119 resulted in food intake that was indistinguishable from controls.
    1 context sentence
    Summary · context
    To evaluate the involvement of melanocortins in spontaneous nocturnal feeding, the synthetic melanocortin receptor agonist, MTII and the antagonist, SHU9119 were administered ICV (third ventricle) alone and in combination.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.